StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for VTGN yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-14 | $0.65 | $0.65 | +0.09% | 0.6M |
| 05-15 | $0.64 | $0.62 | -2.36% | 0.7M |
| 05-18 | $0.63 | $0.60 | -5.45% | 0.5M |
| 05-19 | $0.60 | $0.63 | +4.62% | 0.9M |
| 05-20 | $0.63 | $0.64 | +1.56% | 0.4M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Annual 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $804.00K | $502.00K | $244.00K | $486.00K |
Operating Income | $-55.41M | $-35.86M | $-15.80M | $-55.97M |
Net Income | $-53.41M | $-19.42M | $-15.10M | $-51.42M |
EPS (Diluted) | $-1.46 | $-1.02 | $-0.47 | $-1.67 |
Total Assets | $65.06M | $80.93M | $68.92M | $84.34M |
Total Liabilities | $14.14M | $14.59M | $12.16M | $13.95M |
Cash & Equivalents | $47.37M | $62.79M | $48.98M | $67.13M |
Free Cash Flow OCF − CapEx | $-50.39M | $-32.73M | $-18.91M | Not available |
Shares Outstanding | 36.66M | 33.85M | 31.93M | 30.88M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.